Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 5/20 | 0.46 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.41 |
| ▸ | AOC2 | O75106 | 5/20 | 0.40 |
| ▸ | MAOA | P21397 | 5/20 | 0.40 |
| ▸ | MAOB | P27338 | 5/20 | 0.40 |
| ▸ | DAO | P14920 | 1/20 | 0.40 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.39 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.38 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.38 |
| ▸ | CA2 | P00918 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7217412 | 1.00 | KDM1A (0.46) | KDM1AHSD11B1AOC2MAOAMAOB | |
| SCHEMBL7217406 | 0.78 | HSD11B1 (0.41) | HSD11B1AOC2MAOAMAOBDAO | |
| SCHEMBL12060986 | 0.76 | HSD11B1 (0.42) | HSD11B1AOC2MAOAMAOBDAO | |
| SCHEMBL8039734 | 0.76 | HSD11B1 (0.47) | HSD11B1HDAC3HDAC1HDAC2CYP2D6 | |
| SCHEMBL4934593 | 0.74 | HDAC3 (0.49) | HSD11B1AOC2MAOAMAOBDAO | |
| SCHEMBL229558 | 0.74 | HPGD (0.49) | HSD11B1HDAC3HDAC1HDAC2CYP2D6 | |
| SCHEMBL30887999 | 0.74 | HDAC3 (0.49) | HSD11B1AOC2MAOAMAOBDAO | |
| SCHEMBL2286036 | 0.74 | HPGD (0.49) | HSD11B1HDAC3HDAC1HDAC2CYP2D6 | |
| SCHEMBL5695491 | 0.74 | HDAC3 (0.49) | HSD11B1AOC2MAOAMAOBDAO | |
| SCHEMBL430259 | 0.74 | HDAC3 (0.49) | HSD11B1AOC2MAOAMAOBDAO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6627652-B1 | Treatment of diseases or conditions of the type which are normally treated with retinoid-like compounds is disclosed, with pharmaceutical compositions containing an active compound which is a selective agonist of the RXR retinoid | ALLERGAN, INC. | 2003-09-30 | — | — | US | disclosed |
| US-6624188-B1 | Administered to treat or prevent one or more of the diseases and conditions selected from the group consisting of dermatoses, atherosclerosis and restenosis resulting from neointimal hyperproliferation, non-malignant and | ALLERGAN, INC. | 2003-09-23 | — | — | US | disclosed |
| US-5455265-A | For mammals; skin disorders, cancer, inflammatory disease, cardiovascular diorders, autoimmune diseases and others | ALLERGAN, INC. (US) | 1995-10-03 | — | — | US | disclosed |
| US-5324840-A | Skin disorders | ALLERGAN, INC. (US) | 1994-06-28 | — | — | US | disclosed |